Skoči na glavni sadržaj

Cardiologia Croatica, Vol. 17 No. 9-10, 2022.

Ostalo

https://doi.org/10.15836/ccar2022.167

Association of galectin-3 and significant atherosclerotic epicardial artery disease in patients with chronic coronary syndrome

Ivica Bošnjak orcid id orcid.org/0000-0002-0223-4287 ; University Hospital Centre Osijek, Osijek, Croatia
Dražen Bedeković orcid id orcid.org/0000-0002-8076-4398 ; University Hospital Centre Osijek, Osijek, Croatia
Kristina Selthofer-Relatić orcid id orcid.org/0000-0002-9890-6489 ; University Hospital Centre Osijek, Osijek, Croatia
Hrvoje Roguljić orcid id orcid.org/0000-0002-3747-9305 ; University Hospital Centre Osijek, Osijek, Croatia
Ines Bilić-Ćurčić orcid id orcid.org/0000-0002-8861-5987 ; University Hospital Centre Osijek, Osijek, Croatia

Puni tekst: engleski pdf 142 Kb

str. 167-167

preuzimanja: 79

citiraj

Preuzmi JATS datoteku

Sažetak

Ključne riječi

galectin-3; coronary artery disease; biomarker; chronic coronary syndrome

Hrčak ID:

286915

URI

https://hrcak.srce.hr/286915

Datum izdavanja:

8.12.2022.

Posjeta: 233 *

Copyright: 2022, Croatian Cardiac Society

Date received: 25 October 2022

Date accepted: 10 November 2022

Publication date (print and electronic): November 2022

Volume: 17

Issue: 9-10

Page: 167

Publisher ID: CC 2022 17_9-10_167

DOI: 10.15836/ccar2022.167

Article Information (continued)

Categories:

Subject: Chronic coronary artery disease

KEYWORDS: :

KEYWORDS:

Keyword: galectin-3

Keyword: coronary artery disease

Keyword: biomarker

Keyword: chronic coronary syndrome

Association of galectin-3 and significant atherosclerotic epicardial artery disease in patients with chronic coronary syndrome

[https://orcid.org/0000-0002-0223-4287] Ivica Bošnjak[1][*]

[https://orcid.org/0000-0002-8076-4398] Dražen Bedeković[1]

[https://orcid.org/0000-0002-9890-6489] Kristina Selthofer-Relatić[1][2]

[https://orcid.org/0000-0002-3747-9305] Hrvoje Roguljić[1][2][3]

[https://orcid.org/0000-0002-8861-5987] Ines Bilić-Ćurčić[1][2]

 

[1] University Hospital Centre Osijek, Osijek, Croatia

[2] Faculty of Medicine, J. J. Strossmayer University of Osijek, Osijek, Croatia

[3] Faculty of Dental Medicine and Health Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia

Author notes:

Correspondence to: [*] ADDRESS FOR CORRESPONDENCE: Ivica Bošnjak, Klinički bolnički centar Osijek, J. Huttlera 4, HR-31000 Osijek, Croatia. / Phone: +385-91-922-7756 / E-mail: dribosnjak79@gmail.com

Background: The aim of this study is to examine possible association between serum galectin-3 values and the presence of significant atherosclerotic epicardial artery disease in patients with chronic coronary syndrome.

Patients and Methods: Subjects with suspected coronary artery disease and indication for coronary angiography were included in study. Subject were divided in three groups: a) subject with indication for PCI, b) subject with indication for CABG and control group (without coronary artery disease). Galectin-3 value was measured by enzyme immunoassay (EIA) test.

Results: T-test and ANOVA variance analysis was performed for statistically analysis (SPSS program, version 17.0). The mean value of galectin-3 in the study group was statistically higher than in control group (19.98 ng/ml vs. 9.51 ng/ml, p<0.001). In subgroup analysis there was no statistically significant difference in the values ​​of galectin-3 between the PCI and CABG groups (18.84 ng/ml vs. 21.27 ng/ml (t=7.417, p<0.001).

Conclusion: Galectin-3 has shown potential to be reliable marker for assessment of significant coronary disease existence as well as a predictor of adverse cardiovascular events (1-3).

LITERATURE

1 

Li M, Guo K, Huang X, Feng L, Yuan Y, Li J, et al. Association Between Serum Galectin-3 Levels and Coronary Stenosis Severity in Patients With Coronary Artery Disease. Front Cardiovasc Med. 2022 February 7;9:818162. https://doi.org/10.3389/fcvm.2022.818162 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/35198615

2 

Blanda V, Bracale UM, Di Taranto MD, Fortunato G. Galectin-3 in Cardiovascular Diseases. Int J Mol Sci. 2020 December 3;21(23):9232. https://doi.org/10.3390/ijms21239232 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/33287402

3 

Bosnjak I, Bedekovic D, Selthofer-Relatic K, Billic-Curcic I. Galectin-3: A Heart Failure Biomarker as Sign of Active Coronary Heart Disease. World J Cardiovasc Dis. 2017;7(11):373–9. https://doi.org/10.4236/wjcd.2017.711035

This display is generated from NISO JATS XML with jats-html.xsl. The XSLT engine is libxslt.